Neutral
Charles River Labs is currently trading without any new company-specific catalysts, shifting the focus to its underlying business model, U.S. listing,...
Neutral
Charles River Laboratories International (CRL) has experienced a 7-day winning streak, with its stock climbing 26% and its market cap increasing by ab...
Neutral
James C. Foster, a director at Charles River Laboratories International, Inc. (NASDAQ:CRL), sold 75,000 shares of common stock for $16.8 million at $2...
Neutral
OP Asset Management Ltd acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) during the 1st qu...
Neutral
Charles River Laboratories International, Inc. (CRL) filed a Form 144 showing a proposed resale of 75,000 shares of common stock through UBS Financial...
Neutral
This page displays the price-to-earnings forward ratio for Charles River Laboratories International, Inc. (NYSE: CRL). It indicates that the market wa...
Neutral
This article provides an overview of Charles River Laboratories (CRL), a US-based contract research organization specializing in early-stage drug deve...
Analysts have raised the average 12-month price target for Charles River Laboratories International, Inc. (CRL) stock to $220.29, up from $217.79. Thi...
Neutral
Charles River Laboratories (CRL) has seen its share price recover recently, despite being down year-to-date. While one narrative suggests the stock is...
Charles River Laboratories (NYSE: CRL) director James C. Foster reported exempt, bona fide gifts and trust transfers totaling 366,722 shares of common...
Neutral
Charles River Laboratories (CRL) CEO Birgit Girshick reported exempt transfers of 6,772 shares, primarily structured as bona fide gifts rather than ma...
Charles River Laboratories International recently presented its "Pathway to Purpose" framework and ongoing portfolio reshaping, including divestitures...